GlassScriptPhysician profile
Christie Johnson
NPI 1821485533
$5,334.64
in general payments reported to CMS, 2019-2025
32 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $1,065 · 2023: $1,117 · 2024: $1,319 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,831.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $615.19 | 2022-2024 | |
| Abbvie INC. | $472.82 | 2021-2025 | |
| Stryker Corporation | $294.37 | 2022-2025 | Mild Device Kit |
| Alnylam Pharmaceuticals INC. | $270.86 | 2022-2025 | Amvuttra, Givlaari |
| Neurocrine Biosciences, INC. | $260.57 | 2024-2025 | Ingrezza |
| Genzyme Corporation | $253.93 | 2024-2025 | |
| Novo Nordisk INC | $253.14 | 2021-2022 | |
| Axsome Therapeutics, INC. | $245.52 | 2025 | Symbravo |
| Sage Therapeutics, LLC | $219.52 | 2024-2025 | |
| Biogen, INC. | $199.99 | 2022-2023 | Spinraza |
| Atricure, INC. | $160.00 | 2021 | |
| Ferring Pharmaceuticals INC. | $159.06 | 2023 | Rebyota |
| Medtronic, INC. | $147.24 | 2025 | Symplicity G3 |
| Mirum Pharmaceuticals, INC. | $142.37 | 2023 | Livmarli |
| Jazz Pharmaceuticals INC. | $130.84 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $125.02 | 2024 | Voquezna |
| Sk Life Science, INC. | $124.99 | 2023 | Xcopri |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2024 | |
| Argenx US, INC. | $124.99 | 2025 | Vyvgart |
| Otsuka America Pharmaceutical, INC. | $120.99 | 2023 | Rexulti |
| Lucid Diagnostics INC. | $117.18 | 2024 | |
| Edwards Lifesciences Corporation | $104.64 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Mitris Resilia Mitral Valve |
| Astrazeneca Pharmaceuticals LP | $100.69 | 2023 | Fasenra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.97 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $90.90 | 2025 | |
| Sanofi-Aventis U.S. LLC | $90.22 | 2024 | |
| Gilead Sciences, INC. | $77.71 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $64.62 | 2021 | |
| Davol INC. | $48.65 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $46.90 | 2022 | |
| Abiomed | $35.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.